Qiagen, Maverix Biomics Ink Informatics Co-Marketing Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Maverix Biomics announced today that it has signed a non-exclusive co-marketing agreement with Qiagen to integrate the Maverix Analytic platform with Qiagen's Ingenuity iReport biological data interpretation solution.

According to the company, its platform will complement Qiagen's sample-to-insight workflow by providing easy, three-step, push-button data analysis that includes tools for genome alignment that will help researchers obtain biological meaning from expression data and better understand what may impact disease pathways.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.